Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAINE vs POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Polyethylene glycol 3350 is an osmotic laxative that acts by retaining water in the stool, increasing stool volume, and stimulating colonic peristalsis. Electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate) are included to maintain fluid and electrolyte balance and prevent shifts.
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Bowel cleansing prior to colonoscopy,Treatment of acute constipation in specific formulations
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
4 liters of PEG-3350 and electrolytes solution orally as a single dose for colonoscopy preparation; alternative split-dose regimen: 2 liters evening before and 2 liters morning of procedure. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water once daily, up to 3 days.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Not applicable; PEG 3350 is not metabolized and is eliminated non-kinetically. Clinical effect occurs during colonic transit; residual drug cleared within 24–48 hours post-dose.
Hydrolyzed by plasma esterases.
Polyethylene glycol 3350 is not significantly metabolized; it is excreted unchanged in feces and urine. Electrolytes are absorbed and metabolized according to normal physiological pathways.
Renal excretion of parent drug and metabolites: <5% unchanged.
Primarily fecal (unchanged); minimal renal excretion (<2%) as intact polymer. Electrolytes absorbed and renally excreted.
Minimal; <5% bound to plasma proteins.
PEG 3350: <1% bound to plasma proteins.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
PEG 3350: 0.58 L/kg (confined to extracellular fluid; minimal tissue penetration).
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
Oral: <0.06% for PEG 3350 (systemic absorption negligible). Electrolytes fully absorbed.
No dose adjustment required; negligible systemic absorption.
Contraindicated in patients with GFR < 30 m L/min/1.73 m² due to risk of electrolyte abnormalities and fluid overload. For GFR 30-60: use with caution, monitor electrolytes and volume status; consider split-dose regimen.
No dose adjustment required; negligible systemic absorption.
No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment due to risk of electrolyte disturbances and fluid shifts.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
For colonoscopy: 4 L if ≥ 12 years old; for constipation: 0.5-1.5 g/kg/day (max 17 g/day) in children ≥ 6 months. Safety and efficacy not established for colonoscopy in children < 12 years; alternative polyethylene glycol products available.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
Use with caution due to increased risk of electrolyte imbalance, aspiration, and fluid overload. Consider split-dose regimen, monitor renal function and electrolytes. Lower starting dose for constipation: 8.5 g daily.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
No FDA black box warning.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Risk of fluid and electrolyte abnormalities,Serious arrhythmias in patients with pre-existing electrolyte disturbances,Seizures,Renal impairment,Aspiration risk in patients with impaired gag reflex,Colonic mucosal ulcerations
Hypersensitivity to any component of the formulation.
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,Ileus,Known hypersensitivity to any component
None known.
Avoid solid food during bowel preparation. Clear liquids only: water, clear broth, apple juice, white grape juice, black coffee or tea (no milk), clear sports drinks, gelatin without fruit. No red or purple colored liquids. Avoid alcohol.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Insufficient human data; animal studies not conducted. Use during pregnancy only if clearly needed. No known teratogenicity from limited reports.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
Excretion into breast milk unknown; polyethylene glycol is minimally absorbed systemically. Considered likely compatible with breastfeeding due to low absorption.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
No dose adjustment required; pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety due to minimal systemic absorption.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Administer in divided doses to improve tolerance. Ensure adequate hydration to prevent electrolyte imbalance. Contraindicated in ileus, gastrointestinal obstruction, perforation, gastric retention, or toxic colitis. Use with caution in patients with impaired gag reflex to reduce aspiration risk. Monitor renal function and electrolytes in elderly or debilitated patients.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
Take this medication exactly as prescribed for bowel preparation before colonoscopy.,Mix the powder with clear liquids as directed; do not consume any solid food during preparation.,Drink additional clear fluids throughout the preparation to stay hydrated.,Expect frequent, watery bowel movements; stay near a toilet.,If you experience severe abdominal pain, vomiting, or inability to pass stool, contact your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAINE vs POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, answered by our medical review team.
ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is a Bowel Evacuant that works by Polyethylene glycol 3350 is an osmotic laxative that acts by retaining water in the stool, increasing stool volume, and stimulating colonic peristalsis. Electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate) are included to maintain fluid and electrolyte balance and prevent shifts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAINE and POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. The standard adult dose of POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is: 4 liters of PEG-3350 and electrolytes solution orally as a single dose for colonoscopy preparation; alternative split-dose regimen: 2 liters evening before and 2 liters morning of procedure. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water once daily, up to 3 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAINE and POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is classified as Category C. Insufficient human data; animal studies not conducted. Use during pregnancy only if clearly needed. No known teratogenicity from limited reports.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.